SCHEMBL14617880

SCHEMBL14617880

CC[C@H]1OC(=O)[C@H](OCc2ccccc2)[C@@H](C)[C@@H]1C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 4/20 0.43
PSEN1 P49768 4/20 0.40
PSEN2 P49810 4/20 0.40
APH1B Q8WW43 4/20 0.40
NCSTN Q92542 4/20 0.40
APH1A Q96BI3 4/20 0.40
PSENEN Q9NZ42 4/20 0.40
MAPT P10636 1/20 0.39
CYP2C19 P33261 1/20 0.39
IDO1 P14902 1/20 0.38
PLA2G6 O60733 2/20 0.38
PLA2G4A P47712 1/20 0.38
CTRB1 P17538 1/20 0.37
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
CCKBR P32239 1/20 0.36
CYP1A2 P05177 1/20 0.36
FASN P49327 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16727631 1.00 NAAA (0.43) NAAAPSEN1PSEN2APH1BNCSTN
SCHEMBL25495993 0.96 NAAA (0.43) NAAAPSEN1PSEN2APH1BNCSTN
SCHEMBL18371660 0.96 NAAA (0.43) NAAAPSEN1PSEN2APH1BNCSTN
SCHEMBL10120664 0.96 NAAA (0.43) NAAAPSEN1PSEN2APH1BNCSTN
SCHEMBL769853 0.89 NAAA (0.41) NAAAPSEN1PSEN2APH1BNCSTN
SCHEMBL12869515 0.89 NAAA (0.41) NAAAPSEN1PSEN2APH1BNCSTN
SCHEMBL12869511 0.89 NAAA (0.41) NAAAPSEN1PSEN2APH1BNCSTN
SCHEMBL18522464 0.89 NAAA (0.41) NAAAPSEN1PSEN2APH1BNCSTN
SCHEMBL10177147 0.89 NAAA (0.41) NAAAPSEN1PSEN2APH1BNCSTN
SCHEMBL16689647 0.86 BCHE (0.46) NAAAPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828951-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2014-09-09 US disclosed
US-20130017993-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2013-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130017993-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 NAAA 2040/4885PSEN1 3082/4885PSEN2 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.